MetaCap

Incyte Corp. (INCY)

NASDAQ: INCYHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD

114.63-1.25 (-1.07%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

INCY stock chart

Technical analysis

Key statistics

All statistics
Market cap
$23.36B
52-week range
89.25 – 132.60
Day range
114.28 – 117.51
Volume / Avg
1.54M / 1.62M
Beta
—

52-week range

$89.25$132.60

INCY stock today

Shares of Incyte (INCY) finished lower on Nov 20 at $114.63, a drop of 1.07% or $1.25 per share, versus the S&P 500's 3.70% decline. Shares are 13.6% below their 52-week high of $132.60, set on Jul 28, 2026 and 28.4% above the 52-week low of $89.25, in the middle of the past year's range. INCY is up 16.1% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 12.3%.

At 58.5x trailing earnings, Incyte trades in line with the peer-group median of 54.3x. Its forward P/E of 13.4x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Incyte

Company profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma.

Industry
Biotechnology: Commercial Physical & Biological Resarch
CEO
Mr. William J. Meury
Headquarters
Wilmington, DE
Employees
2,844
Website
incyte.com

Financial highlights

Full financials

In fiscal 2025, Incyte generated $5.14 billion in revenue, up 21.2% from fiscal 2024, its 14th consecutive year of revenue growth. Net income was $1.29 billion (+3845.0% year over year), for a net margin of 25.0% versus a median of 10.0% in the prior 5 years. Gross margin was 92.8% (up from 92.6%) and operating margin 29.5%.

Incyte annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$5.14B$4.24B$3.70B$3.39B$2.99B
Growth+21.22%+14.76%+8.87%+13.67%+11.98%
Net income$1.29B$32.62M$597.60M$340.66M$948.58M
EPS (diluted)$6.41$0.15$2.65$1.52$4.27

Analyst forecast

Forecast

Consensus (28 analysts)

buy

Avg. price target

$132.17+15.31%

  • Strong buy 2
  • Buy 11
  • Hold 14
  • Sell 0
  • Strong sell 1

Target range

Low $100.00High $157.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 29, 2026
EPS actual vs est.
$2.03 vs $-4.27
Surprise
+147.54%

INCY news

All INCY news

Incyte peers

Health Care sector
INCY peer companies
CompanyPrice% ChgMarket capCompare
MEDPMedpace Holdings Inc.610.54-3.70%$17.08Bvs INCY
CRLCharles River Laboratories International Inc.314.32-4.15%$15.06Bvs INCY
ICLRICON plc186.71-1.92%$13.99Bvs INCY
IQVIQVIA Holdings Inc.245.82-1.89%$40.51Bvs INCY
ABSIAbsci Corporation7.51-7.97%$1.30Bvs INCY
OABIOmniAb Inc.4.66-7.36%$679.71Mvs INCY
NRCNRC Health25.16+0.68%$533.93Mvs INCY
MXCTMaxCyte Inc.1.37+7.03%$141.45Mvs INCY

Indexes, lists and sector

Incyte stock FAQ

What is Incyte's stock price today?

INCY last traded at $114.63 as of Nov 20, 4:00 PM EST, down 1.07% on the day. Prices are delayed at least 15 minutes.

Does Incyte pay a dividend?

No. Incyte does not currently pay a regular cash dividend.

What is INCY's P/E ratio?

INCY trades at a trailing P/E ratio of 58.48 and a forward P/E of 13.35, compared with a median of 54.3 for its closest peers.

Is Incyte in the S&P 500?

Yes. Incyte (INCY) is a constituent of the S&P 500 index.

Who is Incyte's CEO?

Mr. William J. Meury is the chief executive officer of Incyte Corp., which has about 2,844 employees.

Has INCY ever split its stock?

Yes. The most recent INCY stock split was a 2-for-1 split on Sep 1, 2000, one of 2 splits on record.

What is the INCY 52-week high?

The 52-week high for INCY is $132.60 and the 52-week low is $89.25. The stock is currently 13.6% below its high.

Compare INCY